Deerfield Management ENGNW Position
Exited8-Fund ConvergenceDeerfield Management exited their position in enGene Holdings Inc. (ENGNW) in Q2 2024, after holding the stock for 2 quarters.
The position was first reported in Q1 2024 and has been tracked across 2 quarterly 13F filings.
ENGNW is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for EG-70 (phase 1) in 75 days (Jun 30, 2026), making the timing of Deerfield's position particularly relevant.
About enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Full company profile →Deerfield Management ENGNW Position History
Frequently Asked Questions
Does Deerfield Management own ENGNW?
No. Deerfield Management exited their position in enGene Holdings Inc. (ENGNW) in Q2 2024. They previously held the stock for 2 quarters.
How many hedge funds own ENGNW?
8 specialist biotech hedge funds currently hold ENGNW, including Perceptive Advisors, BVF Partners, Deep Track Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ENGNW?
Deerfield Management's position in ENGNW was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ENGNW position increasing or decreasing?
Deerfield Management completely exited their ENGNW position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ENGNWCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →